Adverse Outcome Pathways as Versatile Tools in Liver Toxicity Testing

Emma Arnesdotter1, Eva Gijbels1, Bruna Dos Santos Rodrigues1

  • 1Department of Pharmaceutical and Pharmacological Sciences, Entity of In Vitro Toxicology, Vrije Universiteit Brussel, Brussels, Belgium.

Insights

Adverse outcome pathways (AOPs) visualize toxicological mechanisms. These pathways aid in chemical risk assessment, prioritizing substances, and developing new in vitro toxicity tests.

Area of Science:

  • Toxicology
  • Chemical Risk Assessment

Background:

  • Adverse outcome pathways (AOPs) provide a framework to understand and visualize the mechanistic basis of toxicological effects.
  • AOPs consist of a molecular initiating event, key events, key event relationships, and an adverse outcome.
  • Development and evaluation of AOPs should align with Organization for Economic Cooperation and Development guidelines.

Purpose of the Study:

  • To highlight the utility and applications of Adverse Outcome Pathways (AOPs) in toxicology and chemical risk assessment.
  • To emphasize the role of AOPs in understanding hepatotoxicity.
  • To explore the application of AOPs in quantitative structure-activity relationships, prioritization, and in vitro testing.

Main Methods:

  • Conceptual framework development for Adverse Outcome Pathways.
  • Review of existing AOPs, particularly those related to hepatotoxicity.
  • Analysis of proposed applications in risk assessment and testing strategies.

Main Results:

  • AOPs offer a structured approach to toxicological mechanisms.
  • The liver is a common target for systemic toxicity, leading to AOP development for hepatotoxicity.
  • AOPs facilitate quantitative structure-activity relationships, prioritization, and novel in vitro toxicity testing.

Conclusions:

  • Adverse outcome pathways are valuable tools for understanding and predicting toxicological effects.
  • AOPs have significant potential to advance chemical risk assessment and the development of predictive toxicology methods.
  • The structured nature of AOPs supports their integration into regulatory science and testing strategies.

Related Concept Videos

Toxic Reactions: Overview01:26

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
1.2K
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.0K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.5K